drugset
drugset / Trial / NCT03555292

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

NCT03555292 ↗

Phase 2 Unknown 200 enrolled Oriental Neurosurgery Evidence-Based-Study Team
Non-randomizedCrossoverSingle-blindDiagnostic

Summary

To evaluate the potential contribution of amyloid burden, as indexed by 11C-Pittsburgh compound B (PiB) retention, to the progression of cognitive impairments in patients with Parkinson's disease(PD).

Timeline

Start
2017-07-12
Primary completion
2021-05-12
Completion
2021-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 11C-PiB Diagnostic / imaging agent 555 mbq Intravenous

Indications

Parkinson disease